Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials.

At the final visit (day 29), add-on treatment with evenamide 30 mg bid resulted in a statistically significant ( p = 0.012) greater improvement, compared to placebo, in the PANSS subdomain of social functioning, as well as a greater improvement compared to placebo on the life engagement subdomain, although the drug-placebo difference was borderline significant ( p = 0.055; Table 3 ).

also in 11,409 other papers